Browse studies

Find your next paid study

5 recruiting studies matching your filters

A Phase 2, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of ARGX-121 SC in Adult Participants With Primary IgA Nephropathy

The study will assess how ARGX-121 affects immunoglobulin A nephropathy (IgAN) disease outcomes, such as renal function, how it is distributed and eliminated f…

Immunoglobulin A Nephropathy (IgAN)

Estimated

~$75 – $3,000

Actual pay is set by the research site.

argenxNCT07773727

Phase 2

An Open-label, Multicenter Study to Assess the Effect of Zigakibart Treatment on Histologic, Circulating, and Excreted Markers of Kidney Disease and Dysfunction in Adult Patients With IgA Nephropathy.

The purpose of the study is to assess the effect of zigakibart on IgA nephropathy (IgAN) disease progression.

Immunoglobulin A Nephropathy (IgAN)

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Novartis PharmaceuticalsNCT07146906

Phase 3

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Felzartamab in Adults With IgA Nephropathy (PREVAIL)

In this study, researchers will learn more about the use of felzartamab in participants with immunoglobulin A nephropathy (IgAN). IgAN is a kidney disease caus…

Immunoglobulin A Nephropathy (IgAN)

Estimated

~$50 – $2,250

Actual pay is set by the research site.

BiogenNCT06935357

Phase 3

A Single-arm, Multicenter, Phase III Study to Assess Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients of 2 to <18 Years of Age With Primary Immunoglobulin A Nephropathy (IgAN)

The study is an open-label, single arm, multicenter, Phase III study to determine proteinuria reduction, pharmacokinetics (PK), safety and tolerability (includ…

Primary Immunoglobulin A Nephropathy (IgAN)

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Novartis PharmaceuticalsNCT06994845

Phase 4

A Multicenter, Single Arm, Open Label, Pilot Study to Assess the Effect of Atrasentan Alongside Supportive Care on Structural and Functional Changes in Kidneys of Adult Patients With IgA Nephropathy (IgAN)

This multicenter, single-arm, open-label Phase 4 pilot study evaluates the effects of atrasentan added to optimized supportive care on kidney structure and fun…

IgA Nephropathy (IgAN)Immunoglobulin A Nephropathy (IgAN)

Estimated

~$25 – $1,000

Actual pay is set by the research site.

University of Illinois at ChicagoNCT07820995